Appointment of Joint Broker

19^th Sep 2016

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces the appointment of N+1 Singer as Joint Broker to the Company, alongside Panmure Gordon, with immediate effect. Panmure Gordon remains Nominated Adviser to the Company.

EKF Diagnostics Holdings plc Julian Baines, CEO Richard Evans, Finance Director and COO	00 44 29 2071 0570
Panmure Gordon (UK) Limited Peter Steel Paul Fincham	00 44 20 7886 2500
Walbrook PR Limited Paul McManus Lianne Cawthorne	00 44 20 7933 8780 or ekf@walbrookpr.com 00 44 7980 541 893 00 44 7584 391 303

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF launches FDA CLIA-waived β-ketone and glucose POC analyzer to U.S. market

New handheld STAT-Site WB ensures reliable and efficient analysis from whole blood

Supporting reduction of anemia in developing regions in South America

Symposium highlights successful use of EKF’s Hemo Control hemoglobin analyzer in extreme environmental conditions

MEDLAB Dubai - Feb 2020

"The world's largest lab expo" - Medlab Middle East is a leading laboratory and flagship exhibition and Conference spanning across Middle East, Asia and West Europe.

AIM Awards 2019

EKF Diagnostics was delighted to win the AIM Transaction of the Year Award at the AIM Awards 2019.

New R&D facility in Head Office

Special Projects Laboratory opened in EKF’s Cardiff HQ to develop new applications in non-core markets and support other global diagnostics R&D facilities